![](/wp-content/uploads/2023/05/Screenshot-2023-05-04-at-3.04.22-PM.png)
$599
Novo Nordisk, Tandem, Alnylam, and Regeneron Q1 ’23 Earnings
Four cardiometabolic-related news items have been observed: Novo Nordisk (view press release; slides), Tandem Diabetes Care (view press release), Alnylam Pharmaceuticals (view press release; slides), and Regeneron (view press release; slides) hosted their respective Q1 ’23 earnings calls and provided CVRM-related updates. Below, FENIX provides highlights and insights from the earnings calls.